People · Operator
Named in public records as an officer, director or promoter · active 2015–2019 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ideaya Biosciences, Inc. | — | Biotechnology | Series C | $111.4M | $3.9B | 2018 |
| Cabaletta Bio, Inc. | — | Biotechnology | Series C | $88.3M | $2.0B | 2018 |
| RareCyte, Inc. | — | Other | Series B | $79.8M | $103.6M | 2017 |
| Nohla Therapeutics Inc. | — | Biotechnology | Series C | $79.4M | $1.8B | 2016 |
| Spyryx Biosciences, Inc. | — | Biotechnology | Series B | $29.1M | $235.4M | 2015 |
Brian Daniels at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brian Daniels on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| John Taylor | 1 | 10 |
| Timothy Shannon | 1 | 9 |
| Tim Shannon | 1 | 9 |
| Andrew J. Schwab | 1 | 7 |
| Christy Shaffer | 1 | 6 |
| Mark Simon | 1 | 6 |
| Paul Stone | 1 | 5 |
| Robert Shepler | 1 | 4 |
| Jeffrey Stein | 1 | 4 |
| John D. Diekman | 1 | 4 |
| Terry Rosen | 1 | 4 |
| Colleen Delaney | 1 | 4 |
| Jim Johnson | 1 | 4 |
| Lawrence Gozlan | 1 | 3 |
| Frank Witney | 1 | 3 |
| Steven Nichtberger | 1 | 3 |
| Roger Jeffs | 1 | 3 |
| John Diekman | 1 | 3 |
| Yujiro Hata | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.